Browse by Audience
Skip to content
Papers of the Week
Sodium Danshensu Alleviates Bone Cancer Pain by Inhibiting the Osteoclast Differentiation and CGRP Expression.
Authors
Zhang X, Yuan X, Li X, Yu H, Wang T, Zhang C, Wu J, You XAbstract
The morbidity of bone cancer pain (BCP) is on the rise, yet current treatments have limited analgesic efficacy. Sodium Danshensu (SDSS), or sodium 3-(3,4-dihydroxyphenyl)-DL-lactate, exhibits anti-inflammatory, anti-osteoporotic properties. Current research shows that bone cancer pain is closely related to the development of osteoclasts.